ABSTRACT
SARS-CoV-2 viral load measurements from a single specimen type are used to establish diagnostic strategies, interpret clinical-trial results for vaccines and therapeutics, model viral transmission, and understand virus-host interactions. However, measurements from a single specimen type are implicitly assumed to be representative of other specimen types. We quantified viral-load timecourses from individuals who began daily self-sampling of saliva, anterior nares (nasal), and oropharyngeal (throat) swabs before or at the incidence of infection with the Omicron variant. Viral loads in different specimen types from the same person at the same timepoint exhibited extreme differences, up to 109 copies/mL. These differences were not due to variation in sample self-collection, which was consistent. For most individuals, longitudinal viral-load timecourses in different specimen types did not correlate. Throat-swab and saliva viral loads began to rise up to 7 days earlier than nasal-swab viral loads in most individuals, leading to very low clinical sensitivity of nasal swabs during the first days of infection. Individuals frequently exhibited presumably infectious viral loads in one specimen type while viral loads were low or undetectable in other specimen types. Therefore, defining an individual as infectious based on assessment of a single specimen type underestimates the infectious period, and overestimates the ability of that specimen type to detect infectious individuals. For diagnostic COVID-19 testing, these three single specimen types have low clinical sensitivity, whereas a combined throat-nasal swab, and assays with high analytical sensitivity, were inferred to have significantly better clinical sensitivity to detect presumed pre-infectious and infectious individuals.
Significance Statement In a longitudinal study of SARS-CoV-2 Omicron viral loads in three paired specimen types (saliva, anterior-nares swabs, and oropharyngeal swabs), we found extreme differences among paired specimen types collected from a person at the same timepoint, and that viral loads in different specimen types from the same person often do not correlate throughout infection. Individuals often exhibited high, presumably infectious viral loads in oral specimen types before nasal viral loads remained low or even undetectable. Combination oropharyngeal-nasal swabs were inferred to have superior clinical sensitivity to detect infected and infectious individuals. This demonstrates that single specimen type reference standard tests for SARS-CoV-2, such as in clinical trials or diagnostics evaluations may miss infected and even infectious individuals.
Competing Interest Statement
RFI is a co-founder, consultant, and a director and has stock ownership of Talis Biomedical Corp.
Funding Statement
This work was funded by the Ronald and Maxine Linde Center for New Initiatives at the California Institute of Technology and the Jacobs Institute for Molecular Engineering for Medicine at the California Institute of Technology. AVW is supported by a UCLA DGSOM Geffen Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the California Institute of Technology gave ethical approval for this work under IRB protocol #20-1026.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author information:
Alexander VILORIA WINNETT, awinnett{at}caltech.edu, 626-395-3464
Reid AKANA, rakana{at}caltech.edu, 626-395-3464
Natasha SHELBY, tshelby{at}caltech.edu, 626-395-3464
Hannah DAVICH, hannahdavich{at}gmail.com, 626-395-3464
Saharai CALDERA, calderasaharai{at}gmail.com. 626-395-3464
Taikun YAMADA, tyamada{at}pangealab.com, 949-346-9393
John Raymond B. REYNA jreyna{at}zymoresearch.com, 949-346-9393
Anna E. ROMANO, aromano{at}caltech.edu, 626-395-3464
Alyssa M. CARTER amcarter{at}caltech.edu, 626-395-3464
Mi Kyung KIM, mikkim{at}caltech.edu, 626-395-3464
Matt THOMSON, mthomson{at}caltech.edu, 626-395-8782
Colten TOGNAZZINI, ctognazzini{at}cityofpasadena.net, 626-744-6000
Matthew FEASTER, mfeaster{at}cityofpasadena.net, 626-744-6000
Ying-Ying GOH, ygoh{at}cityofpasadena.net, 626-744-6000
Yap Ching CHEW, ychew{at}zymoresearch.com, 949-346-9393
Title and abstract updated; additional data provided.
Data Availability
The data underlying the results presented in the study can be accessed at CaltechDATA: https://data.caltech.edu/records/20223.
